12 16 Although the included trials were of relatively good methodological quality (all were blinded and most of these were randomised, with proper allocation concealment), the major limitation was incomplete outcome data (>20% lost to follow-up) and risk of selective reporting (study protocols were not available).
For our secondary outcomes, lack of blinding and missing outcome data were major issues.
The new regulations will involve 3 major measures: 1.Recognition of all outcome data available, including clinical studies and registry data.
To address the major research questions, the quantitative outcome data will be analysed for the whole trial across the four centres, using General Linear Models.
One major outcome is the expansion of data resources, like the AtGenExpress project, that hold gene expression information for almost all Arabidopsis genes.
Long-term outcome data from three major multicenter trials are still awaited [ 15, 22, 35].
The response rate in the recruitment for outcome data was a major limitation of the study and this would need addressing in future trials.
The three treatment groups were not significantly different in baseline characteristics and baseline data for the major outcome assessment (VAS, Lequesne's functional index and time for climbing up ten steps) (Table 2).
The two treatment groups were not significantly different in demographic data e.g., sex, age, weight, height, duration of OA, location of OA (Table 2) and base-line data for the major outcome assessment (VAS, Lequesne's functional index and time for climbing up 10 steps).
We therefore restricted the interpretation of the pathway analysis to the top 25 IPA-pathways exhibiting the most significant associations and defined three prominent whole-blood gene expression signatures (see below) as the major outcome of the analysis.> -wrap-foot> Dare are given as mean ± standard deviation or as number and percent (in parentheses).
